MPI Research Invests in Gyrolab xP Workstation - Drug Discovery and Development

Gyros AB announced that MPI Research is the first contract research organization (CRO) in North America to secure a second Gyrolab xP workstation, a nanoliter-scale immunoassay platform.

Data from immunoassays underpin many critical decisions within complex workflows for the development of biopharmaceuticals. The automated nanoliter-scale immunoassay platform from Gyros enables project-specific biomarker, pharmacokinetic (PK), immunogenicity assays and impurity tests to be developed quickly, and to easily transfer the running of established assays.

Since installing its first Gyrolab xP workstation in April 2011, MPI Research has developed more than 25 novel assays using the platform. The ability to work with nanoliter volumes maximizes the number of assays that can be performed on samples that are often scarce.

Release Date: June 1, 2012
Source: Gyros AB